Funding for this research was provided by:
janssen pharmaceutical k.k.
Article History
Received: 8 July 2021
Revised: 17 September 2021
Accepted: 22 September 2021
First Online: 22 October 2021
Change Date: 14 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10067-022-06242-8
Declarations
:
: This study was approved by Rheumatology Research Concept Approval Team in accordance with Japanese ethical and legal guidelines. JMDC data is anonymized electronic health insurance claims data which is created and aggregated under the compliance Personal Information Protection Law Article 2, Paragraph 9. Using this data as secondary research analysis does not require informed consent as per the Ethical Guidelines for Epidemiological Research issued by the Japanese Ministry of Health, Labor, and Welfare. This study was designed, implemented and reported in accordance with the Guidelines for Good Pharmacoepidemiology Practices of the International Society for Pharmacoepidemiology, and with the ethical principles laid down in the Declaration of Helsinki. Reporting of claims data was based on International Society for Pharmacoeconomics and Outcomes Research and STORBE guidelines.
: Not applicable.
: Not applicable.
: CM and YI were employees of Janssen Pharmaceutical K.K. and NMS was an employee of Parexel at the time the study was conducted. NMS received payment for the data analysis, quality control, and data management.